Compare ANDE & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDE | WVE |
|---|---|---|
| Founded | 1947 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2005 | 2015 |
| Metric | ANDE | WVE |
|---|---|---|
| Price | $71.96 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | ★ $75.00 | $29.81 |
| AVG Volume (30 Days) | 295.2K | ★ 3.9M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 12.93 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $11,008,928,000.00 | $3,704,000.00 |
| Revenue This Year | $7.28 | N/A |
| Revenue Next Year | $3.57 | $85.67 |
| P/E Ratio | $73.57 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $31.84 | $5.02 |
| 52 Week High | $82.11 | $21.73 |
| Indicator | ANDE | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 39.03 |
| Support Level | $69.11 | $6.81 |
| Resistance Level | $74.83 | $7.67 |
| Average True Range (ATR) | 2.65 | 0.36 |
| MACD | -0.92 | 0.15 |
| Stochastic Oscillator | 38.13 | 28.00 |
Andersons Inc is an agriculture and renewable fuels company. Its operations are classified into two reportable business segments: Agribusiness, which generates maximum revenue, and Renewables. The Agribusiness segment includes merchandising and managing logistics across various commodities, as well as being a manufacturer, distributor, and retailer of agricultural and related plant nutrients. The segment specializes in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. The Renewables segment mainly produces, purchases, and sells ethanol and co-products. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.